Platelets and Blood Cells

Peroxisome proliferator-activated receptor γ and retinoid X receptor transcription factors are released from activated human platelets and shed in microparticles

Denise M. Ray[*1], Sherry L. Spinelli[*2], Stephen J. Pollock[1], Thomas I. Murant[1], Jamie J. O'Brien[1], Neil Blumberg[2], Charles W. Francis[3], Mark B. Taubman[4], Richard P. Phipps[1]

University of Rochester Medical Center, [1]Environmental Medicine; [2]Pathology and Laboratory Medicine; [3]Medicine: Hematology-Oncology; [4]Center for Cellular and Molecular Cardiology, Rochester, New York, USA

Summary

Peroxisome proliferator-activated receptor γ (PPARγ) and its ligands are important regulators of lipid metabolism, inflammation, and diabetes. We previously demonstrated that anucleate human platelets express the transcription factor PPARγ and that PPARγ ligands blunt platelet activation. To further understand the nature of PPARγ in platelets, we determined the platelet PPARγ isoform(s) and investigated the fate of PPARγ following platelet activation. Our studies demonstrated that human platelets contain only the PPARγ1 isoform and after activation with thrombin, TRAP, ADP or collagen PPARγ is released from internal stores. PPARγ release was blocked by a cytoskeleton inhibitor, Latrunculin A. Platelet-released PPARγ was complexed with the retinoid X receptor (RXR) and retained its ability to bind DNA. Interestingly, the released PPARγ and RXR were microparticle associated and the released PPARγ/RXR complex retained DNA-binding ability. Additionally, a monocytic cell line, THP-1, is capable of internalizing PMPs. Further investigation following treatment of these cells with the PPARγ agonist, rosiglitazone and PMPs revealed a possible transcellular mechanism to attenuate THP-1 activation. These new findings are the first to demonstrate transcription factor release from platelets, revealing the complex spectrum of proteins expressed and expelled from platelets, and suggests that platelet PPARγ has an undiscovered role in human biology.

Introduction

Peroxisome proliferator-activated receptor γ (PPARγ), a ligand activated transcription factor, is one of three PPAR subtypes (also PPARα and PPARδ/β) (1). PPARγ is widely expressed by adipose tissue (2) and immune system cells (3, 4). Two PPARγ isoforms, PPARγ1 and PPARγ2, are products of the same gene, but result from differential promoter use, and alternative RNA splicing (5). The PPARγ2 isoform is mainly expressed in adipose tissue (2), whereas PPARγ1 is more widely expressed (5). Although PPARγ was originally described as a nuclear receptor, it has both cytoplasmic and nuclear distribution (3, 6). As a transcription factor, PPARγ functions as a heterodimer with the Retinoid X Receptor (RXR) to initiate transcription of genes containing PPAR response elements (PPRE) (7).

PPARγ ligands include the synthetic clinically used thiazolidinediones (8) (rosiglitazone and pioglitazone) and naturally occurring ligands such as 15-deoxy-$\Delta^{12,14}$-prostaglandin J_2 (15d-PGJ$_2$) (9, 10) and lysophosphatidic acid (LPA) (11). PPARγ and its ligands are widely studied because they are potent insulin sensitizers used to treat type 2 diabetes mellitus. Furthermore, rosiglitazone reduces the incidence of type 2 diabetes mellitus in at risk patients (12).

Recently, we reported PPARγ expression in human platelets (13), suggesting a new role for platelets in inflammation (14). Upon activation, platelets release pro-inflammatory mediators, including IL-1β, sCD40L, TGFβ, and TXA_2, some of which activate endothelial cells and produce chemokines to recruit inflammatory cells (15–17). Emerging evidence implicates inflammation in the development of type 2 diabetes mellitus and cardiovascular disease (18–20). PPARγ ligands dampen platelet activation and studies in human patients with atherosclerosis have shown that TZD agonists of PPARγ reduce platelet activation, not only to inhibit plaque progression, but remarkably to promote regression of existing atherosclerotic plaques (21).

Platelet activation by physiological agonists or high shear stress leads to the highly regulated formation and release of their contents in soluble form or via membrane-bound vesicles (22). One vesicle is the platelet microparticle (PMP) ranging in size from 0.1 to 1.0 μm (23) that surface-expose proteins to regulate inflammatory (24, 25) and hemostatic processes (26, 27). PMPs are also involved in pathogenic processes and elevated in atherosclerosis (28), type 2 diabetes mellitus (29), and cancer (30).

Our laboratory recently discovered that human platelets express PPARγ and that PPARγ ligands attenuate platelet-release of the pro-inflammatory and pro-coagulant mediators sCD40L and TXA_2, a cyclooxygenase product that enhances platelet activation (13). Herein, we investigated the PPARγ isoform and fate in activated human platelets. Surprisingly, we found that PPARγ is complexed with RXR and is released from activated platelets. Some of the released PPARγ is associated with PMPs, which can be transferred to THP-1 cells. Moreover, in the presence of the PPARγ agonist, rosiglitazone, and PMP-containing PPARγ, THP-1 activation is dampened suggesting a novel transcellular mechanism of regulation.

Materials and methods

Blood collection and preparation of washed human platelets

Whole blood was obtained under IRB approval from male and female donors (21–55 years of age) that were NSAID-free for two weeks prior to donation with a body mass index (BMI) ≤ 25. Blood was collected by venipuncture into a citrate phosphate dextrose adenine solution containing collection bag (Baxter Fenwal, Round Lake, IL, USA) or Vacutainer tubes containing buffered citrate sodium (BD Biosciences, Franklin Lakes, NJ, USA). Platelet-rich plasma (PRP) was obtained by centrifugation (250xg/15 min/room temperature (RT)), diluted with an equal volume of Krebs-Ringer Bicarbonate Buffer (KRB) (Sigma, St. Louis, MO, USA) pH 5.0 containing 15 mM sodium bicarbonate and 19 mM sodium citrate and centrifuged (200xg/10 min). The platelet pellet was washed in KRB pH 6.0, centrifuged (950xg/10 min), and resuspended in KRB pH 7.4. Platelets were counted on an Abbott Cell-Dyn 1700 (Abbott Park, IL, USA). On average, $5.5x10^{10}$ platelets/unit of blood were obtained, and the platelet purity was 99 to 99.99% as described (13).

Platelet activation

Nine $x10^7$ platelets in KRB pH 7.4 were incubated (37°C) with platelet activators: Thrombin 0.8 U/ml (Sigma), Thrombin Receptor Activator Peptide-6 (TRAP) 50 μM (Bachem Biosciences Inc., King of Prussia, PA, USA), collagen 10 μg/ml (Chrono-log Corporation, Havertown, PA, USA), adenosine diphosphate (ADP) 10 μM (Chrono-log Corporation), and phorbol 12-myristate 13-acetate (PMA) 0.2 μM (Sigma). After treatment, platelets were centrifuged (1200xg/1 min/RT), and supernatants and pellets analyzed. For some studies, platelets were incubated with the cytoskeletal inhibitor, Latrunculin A (Lat A) (Sigma), for 20 min prior to activation.

Culture of megakaryocyte cell lines

Meg-01 (31) and M-07e cells (32) were cultured in RPMI 1640 medium (Gibco, Grand Island, NY, USA) as previously described (13). Meg-01 and M-07e are both human leukemia cell lines at the megakaryoblast stage of development.

Western blots for PPARγ and RXR

Total protein was isolated from platelets as described (13). For platelet mediator release experiments, equal volumes of supernatant or lysate were used for Western blot analysis for PPARγ using a rabbit polyclonal anti-PPARγ (BIOMOL), a mouse monoclonal anti-PPARγ2 (Chemicon International, Temecula, CA, USA) and for RXR using a rabbit polyclonal anti-RXR (Santa Cruz Biotechnology, Santa Cruz, CA, USA) as described (10, 13, 33). Human adipose tissue was used as a positive control for PPARγ and RXR.

Co-immunoprecipitation (co-IP) of PPARγ and RXR

Lysates from unactivated platelet and supernatants from TRAP-activated platelets were immunoprecipitated for PPARγ using an anti-PPARγ antibody (Santa Cruz) or for RXR using a rabbit polyclonal antibody (Santa Cruz). Control samples were incubated with a mouse IgG1 isotype control antibody (for PPARγ control IP) or with rabbit serum (for RXR control IP) (both from Santa Cruz). Total protein (50 μg) was incubated in IP buffer (50 mM HEPES [pH 7], 0.1% NP-40, 250 mM NaCl, 5 mM EDTA, 10 mM NaF, 0.1 mM Na_3VO_4, 50 uM $ZnCl_2$ supplemented with 0.1 mM phenylmethylsulfonyl fluoride, 1 mM dithiothreitol, and protease inhibitor cocktail) with antibody (5 μg) overnight at 4°C. Antibody complexes were precipitated using Protein G Plus Agarose (Santa Cruz) (2 hours/4°C). Complexes were pelleted and washed five times in IP buffer. The beads were denatured by boiling in Western buffer (Sigma). Western blots for PPARg and RXR were performed as described above.

Real-time RT-PCR for RXR

RNA was isolated from Meg-01 cells, platelets from three individual donors, and human adipose tissue as a positive control using an RNeasy Kit according to the manufacturer's protocol (Qiagen, Valencia, CA, USA). Reverse transcription reactions contained 0.5 μg of RNA and were performed as described (10). A negative control without RT did not produce product. Quantitative real-time RT-PCR was performed for RXRα, RXRβ, and 7S rRNA as a control as published (34). The cycle threshold

values were normalized to 7S rRNA and compared to the normalized value for human adipose tissue.

Electrophoretic mobility shift assay (EMSA)
Gel shift assay of supernatants from unactivated or activated human platelets and PMP lysates was carried out as previously described (13). The EMSA consensus sequence used for PPARγ was (5'CAAAACTAGGTCAAAGGTCA-3').

PPARγ activity assay
Samples for the PPARγ activity assay were prepared as described for the EMSA. Specific PPARγ DNA-binding was assessed in platelet supernatants and PMP lysate (5 mg) using a TransAM PPARγ activity assay kit (Active Motif) as described (13). PMP lysates were untreated or pretreated with PPARγ agonist, rosiglitazone -20 µM for 30 min at 37°C prior to DNA-binding.

Platelet microparticle (PMP) isolation
PMP isolation was previously described by Heijnen et al. (35). Final samples of washed platelet suspension contained $2–4 \times 10^9$ cells. The PMP pellet and PMP-poor supernatant were analyzed by Western blot or the pellet was resuspended in 1% paraformaldehyde (PFA) containing 5 mM EDTA for microscopic studies. More than 90% of the isolated particles were <1 µm in size as determined by light microscopy.

Immunofluorescence
Platelets applied to poly-L-lysine coated polystyrene chamber slides (BD Bioscienc es, San Jose, CA, USA) were fixed in 2% PFA and blocked with normal goat serum. Platelets were incubated with a PPARγ antibody (BIOMOL) in 0.005% Triton® X-100. PMPs were incubated in PBS containing either a chicken anti-PPARγ (Novus Biologicals, Littleton, CO, USA) or anti-RXR antibodies. After washing, a goat anti-rabbit-FITC (Jackson ImmunoResearch) donkey anti-chicken-FITC (Genway

Biotech, Inc., San Diego, CA, USA), or goat anti-rabbit allophycocyanin (APC) (Santa Cruz) were used. Normal rabbit serum served as a control for polyclonal antibodies or secondary antibody only for the chicken antibody. Following fixation, THP-1 cells were labeled with a mouse anti-PKCα (BD Biosciences, San Jose, CA, USA) (in 0.05% triton X-100, 1:250, RT, 1 h). After washing, cells were labeled with anti-mouse IgG conjugated to biotin (1 h in triton/ RT) and then washed. Finally, strepavidin conjugated to APC was added (1 h in triton/ RT). Slides were treated with Vectashield mounting medium (Vector Laboratories, Burlingame, CA, USA). Images were acquired using an Olympus BX51 light microscope (Olympus, Melville, NY, USA), photographed with a SPOT camera and analyzed with SPOT RT software (New Hyde Park, NY, USA).

Live imaging microscopy
Live images were acquired using CytoViva technology (Aetos Technologies, Inc., Auburn, AL, USA). This is a high-resolution, optical illumination microscopy that provides resolving power below 100 nm and allows imaging of live samples in real time.

PPARγ uptake studies
A promonocytic cell line, THP-1, was cultured as described for Meg-01. 5×10^5 cells/0.5 ml were plated in 12-well culture plates with fresh medium. Isolated PMPs, derived from 1×10^9 platelets, were labeled with a PPARγ-FITC antibody, and added to THP-1 cell culture and incubated (37°C/1 h). PMP labeled with secondary antibody only served as a negative control. THP-1 cells were centrifuged and washed twice in PBS. A fraction of the cells were fixed in 1% PFA and prepared for microscopy. Serial images were captured using a Leica TCS SP Spectral Confocal microscope (Leica, Heidelberg, Germany), photographed with a SPOT digital camera and analyzed with Image-Pro Plus v.3 software. Remaining THP-1 cells were analyzed by Western blot for PPARγ (chicken anti-PPARγ) followed by donkey anti-chicken-HRP (Jackson Immunologicals, West Grove, PA, USA), and mouse monoclonal anti-actin followed by goat anti-mouse-HRP (both from Oncogene research products). Transcellular studies were carried out as described above for uptake. PPARγ agonists (rosiglitazone, 20 µM) and PMP were added to THP-1 cells and coincubated for one hour. The cells were harvested as described above.

Statistical analysis
Experiments were repeated from a minimum of three individuals and as many as 20 individuals except where stated. Differences between means were evaluated by one-way ANOVA. A value of less than 0.05 was considered statistically significant.

Results

Human platelets contain PPARγ1, but not PPARγ2 protein
We previously demonstrated that human platelets and megakaryocytes express PPARγ (13). To determine PPARγ isoform expression (γ1 and/or γ2) in platelets and Meg-01 cells, a Western blot was preformed using a monoclonal antibody specific for the unique amino-terminus of PPARγ2 (Fig. 1). The human


Figure 1: Human platelets contain only PPARγ1 protein.
Western blot analysis for PPARγ2 (top) reveals Meg-01 cells do contain PPARγ2 protein. Platelets from two individuals are negative for PPARγ2. Adipose tissue (AT) was used as a positive control. The bottom blot depicts total PPARγ (both PPARγ1 and 2) in the same samples. (10 µg protein/lane).

Figure 2: PPARγ is released from activated platelets. Platelets were activated with thrombin, TRAP, collagen, PMA, or ADP for the indicated times and a Westen blot for PPARγ was performed on supernatants and cell lysates (equal volume). Results are representative of at least 10 experiments.


Figure 3: Platelet PPARγ release is inhibited by Lat A. Platelets were pre-incubated with the actin cytoskeleton inhibitor Lat A for 20 min and then activated with PMA. Cell-free supernatants were examined by Western blot for PPARγ (equal volume).

megakaryoblast cell line, Meg-01, expressed low levels of PPARγ2. In contrast, washed human platelets did not express detectable PPARγ2. All samples contained PPARγ as determined using an antibody that recognizes the common region of PPARγ1 and PPARγ2. Purified platelets from six individual donors were all negative for PPARγ2.

Human platelets release PPARγ upon activation
We next investigated PPARγ's fate in activated platelets. Interestingly, platelet PPARγ levels decreased following thrombin activation (Fig. 2), suggesting that PPARγ was released. Indeed, abundant PPARγ protein was detectable in thrombin-activated platelet supernatants as early as 30 sec after activation. Conversely, PPARγ was detected within unactivated platelets, while corresponding supernatants contained little PPARγ. In addition to thrombin activation, TRAP, collagen, and PMA all induced PPARγ release from platelets within 30 sec (Fig. 2). PPARγ re-

lease was seen with the weak platelet agonist ADP; however, PPARγ was not detectable in supernatants until five minutes after exposure (Fig. 2).

Latrunculin A blocks PPARγ release
PPARγ release was blocked by Latrunculin A (Lat A), which interferes with actin cytoskeletal reorganization (36). Flaumenhaft et al. recently demonstrated that exposure to Lat A inhibits α-granule release (36). To ascertain PPARγ release kinetics, platelets were exposed to Lat A prior to PMA treatment, and cell-free supernatants examined for PPARγ. PMA treatment of platelets (Fig. 3) strongly released PPARγ compared to untreated samples. Pre-treatment of platelets with Lat A (200 μM) substantially inhibited PPARγ release, suggesting that the protein may be localized to α-granules (Fig. 3). Further morphologic and release rate data will be necessary to pinpoint the subcellular location of PPARγ.

Human platelets express the PPARγ binding partner RXR
In nucleated cells, PPARγ forms a heterodimer with the Retinoid X Receptor (RXR) during transcription. We investigated in human platelets RXR expression, utilizing an antibody recognizing all forms of human RXR (RXRα, RXRβ, and RXRγ). Figure 4A shows that platelets purified from three individuals and two human megakaryocyte cell lines, Meg-01 and M-07e, express RXR protein. The two bands apparent in some lanes most likely represent different RXR forms. Platelets activated with TRAP, collagen, or thrombin all released RXR (Fig. 4B). Co-IP studies were performed using an anti-PPARγ antibody and Western blotting for RXR and by the reciprocal experiment using an anti-RXR antibody for IP and Western blotting for PPARγ. Figure 4C demonstrates that PPARγ and RXR co-IP in both platelet lysates and TRAP-activated platelet supernatants. Since platelets contain some mRNAs (37), platelets and Meg-01 cells were evaluated for the presence of RXR mRNA. Real-time PCR was performed for RXRα and RXRβ, and levels were compared to adipose tissue which contains abundant RXR mRNA (Fig. 4D). Platelets express 7S rRNA, which was used as a control for normalization; however, compared to adipose tissue and Meg-01 cells, which express RXRα and RXRβ RNA, platelets had little to no detectable product for either form of RXR.

Figure 4: Human platelets express RXR protein and release RXR upon activation. A) Platelets and Meg-01 and M-07e human megakaryocyte cell lines were analyzed for RXR protein expression (10 μg/lane). B) Platelets were deactivated or activated with TRAP, collagen, or thrombin (5 min) and cell-free supernatants analyzed for RXR protein. C) PPARγ and RXR immunoprecipitations were performed using deactivated platelet lysates (PL), and supernatants (PS) from TRAP-activated platelets. IP samples contained 50 μg of total protein and an antibody to either PPARγ or RXR. The PPARγ IP was blotted for RXR and the RXR IP was blotted for PPARγ. Control antibody IPs were negative for RXR and PPARγ. D) Real-time RT-PCR was performed for RXRα and RXRβ RNA isolated from platelets, Meg-01 cells, and human adipose tissue. The cycle threshold ratio of RXR to 7S rRNA was calculated and compared to adipose tissue (set at a ratio of 1).

PPARγ released from human platelets retains DNA-binding activity

To examine PPARγ release further, and to detect whether intact DNA-binding complexes of PPARγ were expelled, the TransAM PPARγ activity assay (Fig. 5) and gel shift assay (EMSA) (data not shown) were used. Platelets were deactivated or activated with thrombin, TRAP, or collagen for 0.5 min and 1 min at which time cell-free supernatants were collected. The PPARγ activity assay utilizes a plate-bound PPRE-DNA oligonucleotide and a secondary incubation step with a PPARγ antibody. Increased binding to the DNA probe was observed in platelet supernatants with all three platelet activators as compared to the untreated control (Fig. 5). Additionally, supernatants were incubated with a radiolabeled PPRE, and DNA-binding was assessed by EMSA.


Figure 5: The PPARγ released from human platelets retains DNA-binding activity. Platelets were deactivated (NT = no treatment) or activated with thrombin, TRAP, or collagen (0.5 or 1 min). A PPARγ activity assay was performed using platelet supernatants. PPARγ was detected using a PPARγ antibody. The results are graphed as the OD value at 450 nm and are the average of duplicate samples. Error bars represent the standard deviation from the mean. The PPARγ activity released from the treated versus untreated platelets was significantly greater (*p<0.0001) for all three agonists at both 0.5 min and 1.0 min time points. The PPARγ activity released was significantly greater for each agonist at 1.0 min than at 0.5 min at (**p<0.05) for all three agonists.

The EMSA results confirmed the PPARγ activity assay results, showing an increase in PPARγ DNA-binding in supernatants from activated platelets. A cold competitor (CC) control was performed for binding specificity using the 0.5 min TRAP sample and showed no shifted band.

PMPs from activated platelets contain PPARγ and RXR

To determine whether platelet-released PPARγ was contained in PMPs, activated platelets and purified PMPs were labeled with a PPARγ antibody and visualized by fluorescence microscopy (Fig. 6). A substantial portion of platelet PPARγ appeared to be compartmentalized in granules (Fig. 6A). The staining clearly demonstrates that PMPs contain PPARγ protein (Fig. 6B). In addition, PMPs contain RXR as depicted in the immunofluorescence staining in Figure 6C. An overlay of PPARγ and RXR staining in microparticles revealed most PMPs contain both PPARγ and RXR, although some PMPs are not double stained (Fig. 6D), white arrows). Purified PMPs were also lysed and analyzed by Western blot for PPARγ and RXR (Fig. 7A), and were positive for both proteins. The supernatant from the PMP isolation (PMP-poor fraction) was analyzed for PPARγ (Fig. 7B) and showed that there is PPARγ in PMP-poor fractions, suggesting that not all PPARγ is contained in PMPs. Since PMPs contained both PPARγ and RXR, an EMSA for PPARγ DNA-binding activity was performed on PMP lysates (Fig. 7C). The PMP PPARγ bound to the PPRE DNA element as indicated by the shifted band. Additionally, PMPs isolated from TRAP-activated platelets were positive for PPARγ activity using the TransAM

Figure 6: Microparticles released by activated human platelets contain PPARγ and RXR. Platelets were activated with TRAP and PMPs isolated. Both the platelet (A) and PMP (B) fractions were labeled with an anti-PPARγ antibody and visualized by fluorescence microscopy (final magnification 1000X). B) Immunofluorescence labeling of PMPs with anti-PPARγ (green) or C) anti-RXR (red) antibodies indicates that PMPs co-express PPARγ and RXR (overlay) D) (final magnification 1000X). White arrows indicate PMPs that are single positive for either PPARγ or RXR.


Figure 7: PMP-derived PPARγ retains DNA-binding activity. A) Purified PMPs were analyzed for PPARγ and RXR protein expression (10 μg/lane). B) PMPs were pelleted by centrifugation and the PMP-poor supernatant analyzed for PPARγ (5 μg protein/lane). Each lane in (A) and (B) represents a different donor (1–3). C) An EMSA was performed using PMP lysate incubated with radiolabeled probe containing the PPAR DNA consensus sequence. FP-free probe, CC-PMP sample #3 incubated with cold competitor. D) Top graph: A PPARγ activity assay was performed on isolated PMPs. DNA-bound PPARγ was detected using a PPARγ antibody. The results are graphed as the OD value at 450 nm. The platelet microparticle preparations from treated versus a no treatment control (NT) had PPARγ activity that was greater at $*p < 0.0001$ for each of the three experiments. Bottom graph: PPARγ activity was repeated on PMPs in the presence of the PPARγ agonist, rosiglitazone (Rosi, 20 μM), to detect augmentation of DNA-binding. E) PMPs containing fluorescently labeled PPARγ were incubated with THP-1 cells. PPARγ-FITC labeled PMP are internalized as represented in an overlay of corresponding fluorescence and brightfield confocal images (final magnification 1000X). F) THP-1 cells were incubated with or without PMP, and analyzed for PPARγ protein and actin.

PPARγ assay (Fig. 7D, top graph). These results argue that PMP PPARγ is already bound by an endogenous ligand. To assess the extent of PMP PPARγ DNA-binding, we used the TransAM PPARγ assay to measure whether DNA-binding could be augmented or inhibited following treatment with the PPARγ agonist rosiglitazone, or the antagonist, GW9662, respectively. Our results are representative of three individual experiments, but shown for one individual donor in Figure 7D (bottom graph) and demonstrates that in the presence of rosiglitazone, there is only a modest increase in binding activity in the PPARγ agonist treated PMP compared to untreated. We previously showed that PPARγ derived from platelet lysates also binds DNA without treatment with PPARγ agonists, but binds three- to four-fold more strongly in the presence of PPARγ agonists (13). We hypothesize that the marginal increase in PMP PPARγ DNA-binding following treatment with rosiglitazone is consistent with the idea that PPARγ in PMPs is already bound to an endogenous ligand, or to a ligand and co-activator. Such associations would stabilize the PPARγ/RXR complex. Moreover, the addition of the antagonist GW9662 alone does not significantly block PMP PPARγ binding to DNA (data not shown). GW9662 acts by potently inhibiting PPARγ binding activity via covalent modification of a cysteine residue in the ligand-binding site of PPARγ and may destabilize PPARγ conformation (38). Clearly, future studies are warranted to understand the mechanism(s) that governs PMP PPARγ DNA-binding and function.

Platelet-released PPARγ is transferred to THP-1 cells
Microparticles have been reported to be taken up by other cells such as macrophages (23). It was tested whether PPARγ-containing PMPs could be taken up by THP-1 cells using PPARγ-FITC labeled PMPs. Our results show that microparticles containing PPARγ are transferred to THP-1 cells as demonstrated by the appearance of FITC label in optical serial sections of THP-1 cells (Fig. 7E). In support of the fluorescence data, PPARγ protein levels were measured by Western blot in THP-1 cells incubated with and without PMPs for 1 hour. Although THP-1 cells contain endogenous PPARγ, PPARγ expression in these cells is marginal until they are activated to induce upregulation of PPARγ protein (39). The short 1 hour incubation time was adequate for cells to take up PPARγ-containing PMPs, but was not long enough for THP-1 cells to possibly be stimulated to make their own PPARγ. Figure 7F demonstrates that PPARγ levels were increased in cells incubated with PMPs. Densitometry measurements (n=3) indicate an average 2.5 ± 0.7 -fold increase in PPARγ protein levels in PMP treated THP-1 cells compared to no treatment.

Transcellular effects of PMP-derived PPARγ in THP-1 cells
Recently, von Knethen et al. reported that sequestration of PKCα in the cytosol leads to desensitization of monocytes/macrophages during sepsis (39). During activation of the PPARγ expressing macrophage cell line, RAW 264.7, PKCα is translocated from the cytosol to the plasma membrane where it is subsequently depleted. In the presence of the synthetic PPARγ agonist, rosiglitazone, von Knethen et al. demonstrated that PKCα translocation was abrogated by direct protein/protein interaction with PPARγ1 (39). As reported herein, platelets contain the PPARγ1 isoform only. To investigate whether internalized PMP PPARγ may elicit a similar function, we co-incubated THP-1 cells (a low PPARγ expressing cell line) for 1 hour with PMPs fluorescently labeled for PPARγ1 and rosiglitazone (Fig. 8), and examined cell morphology and PMP PPARγ localization using both reflected light differential interference contrast (DIC) and fluorescence microscopy. Our data demonstrate that PMP treatment alone strongly activates THP-1 cells (Fig. 8A, column 1, compare untreated and PMP), as evidenced by the formation of pseudopodia (purple arrow), lamellae (red arrows) and a general flattening of the cells when compared to untreated cells that remain more rounded. In the presence of rosiglitazone alone, the cells appeared similar to untreated cells (data not shown). Conversely, co-incubation of both rosiglitazone and PMPs demon-


Figure 8: PMP-derived PPARγ dampens THP-1 cell activation in the presence of Rosiglitazone. THP-1 cells (1×10^6 cells) were incubated with and without purified PMPs from 1×10^9 platelets and labeled for PPARγ (green). Cells were thoroughly washed and applied to chamber slides. Fixed and permeabilized cells were stained with anti-PKCa (red). Cell nuclei were counterstained for DAPI (blue). A) Reflected light differential interference contrast (DIC) microscopy was used to reveal changes in cellular morphology as shown in column 1 following various treatments. THP-1 cells are activated by PMP treatment. The overlay in column 2 demonstrates PMP PPARγ and PKCa localization with respect to the nucleus and cytosol. THP-1 cell activation is attenuated in the presence of both PMP PPARγ and rosiglitazone when compared to PMP alone as evidenced by cell morphology (column 1) and cytosolic retention of PKCa in PMP containing cells (column 2). The data is representative of three individual experiments.in the presence of rosiglitazone (Rosi, 20 μM) and PMPs. B) Live images of THP-1 cells untreated or incubated with PMPs (< 1 hour or 1 hour) show changes in cell morphology following activation.

strates a dampening of THP-1 activation in cells that take up PPARγ-labeled PMPs (Fig. 8, column 1, Rosi/PMP). These cells appear to have some features of both unactivated and activated cells, yet the observed cellular changes do not fully resemble that of PMP activated THP-1 cells. For example, the Rosi/PMP treated cells have some pseudopodia formation (purple arrows), but they are not as flat as the PMP treated cells and have not formed lamellae-type structures. Fixed and permeabilized THP-1 cells were also stained for PKCα and the nucleus counterstained to investigate PMP PPARγ and PKCα localization. Consistent with the changes in cellular morphology, cells activated with platelet-derived PMPs exhibit membrane localization of PKCα (Fig. 8A, column 2, green arrow) as well as reduced PKCα fluorescence, suggesting depletion of PKCα protein in these cells (Fig. 8A, column 2, white arrows indicate PMP PPARγ uptake). Following co-incubation of both PPARγ-containing PMPs and rosiglitazone, THP-1 cells that contain fluorescent PMPs retain more PKCα fluorescence that is dispersed mainly throughout the cytosol, suggesting a PPARγ dependent transcellular attenuation of THP-1 activation (Fig. 8A, column 2, Rosi/PMP). Further investigation is required in order to determine the mechanism of this transcellular attenuation of THP-1 activation and to specifically localize PMP PPARγ.

We are currently developing novel techniques via live imaging of cells in culture that allow us to study biological processes in real time (Fig. 8B). Live imaging of THP-1 cells clearly show changes in the plasma membrane (PM) upon addition of PMPs (Fig. 8B, compare untreated cell to PMP treated cells [< 1 h and 1 h]), such as the dynamic formation of pseudopodia (purple arrow) and lamellae-type structures (red arrow), which are evident within the first hour of treatment. Additionally, within the lamellae-type structures, there is accelerated movement of cellular contents that is not witnessed in untreated cells. This activity is consistent with cytoskeletal rearrangement as well as other changes associated with cellular activation. This new high definition microscopic technology will be used in the future to further visualize PMP activation and real time uptake of fluorescent PMP PPARγ under various conditions including PPARγ agonist treatment of cells.

Discussion

The results presented herein are the first to demonstrate that PPARγ, in particular PPARγ1, is released from human platelets in response to platelet agonists. Interestingly, human platelets also contain the PPARγ binding partner RXR, and some PPARγ is released from activated platelets as a functional heterodimer (PPARγ/RXR). The expelled PPARγ was found in platelet releasate and associated with PMPs, and both forms of released PPARγ retain functional DNA-binding capability. To our knowledge, this is the first report to demonstrate release of transcription factors from activated human platelets. Transcription factors thus constitute a new class of platelet-released molecules that could have a broad range of biological effects and possibly be used as biomarkers of platelet activation.

We found that PPARγ release could be prevented by pretreatment with Lat A, an inhibitor of cytoskeletal reorganization. This suggests that PPARγ release is partly dependent on cytoskeletal changes associated with platelet activation (36). It is

known that PMP formation and release involves cytoskeletal rearrangement (40) and is necessary for α-granule release (36), suggesting that PPARγ may be a constituent of α-granules. Future studies will be necessary to clearly define the subcellular localization of PPARγ.

PPARγ from both unactivated and activated platelets binds the PPAR DNA consensus sequence in the absence of added PPARγ agonists (13). This activity can be further enhanced by the addition of natural and synthetic PPARγ agonists. Our new data show that PMP PPARγ also retains substantial DNA-binding activity in the absence of added ligand, but in contrast to platelets, this activity is only modestly enhanced by agonist addition. In fact, PMPs are generated from activated platelets, which produce an endogenous ligand that promotes strong DNA-binding. Upon activation, platelets generate and release lysophosphatidic acid (LPA), a known PPARγ ligand (11). Moreover, Johnson et al. have shown that PPARγ /RXR heterodimer stability is achieved by ligand binding and further strengthened by co-activator association (41). Our results suggest that PMPs from activated platelets contain stable ligand bound to PPARγ /RXR heterodimers. Therefore, we were not surprised when GW9662 did not substantially inhibit PMP PPARγ DNA-binding activity, using an in-vitro assay. GW9662 is an irreversible antagonist of PPARγ. It has been hypothesized that the binding of GW9662 does not stabilize PPARγ to the extent that an agonist does and thus, dampens its activity. While the PMP PPARγ/RXR complex released from activated platelets does bind DNA, it may also function via a non-genomic mechanism.

PPARγ was originally characterized as a "transcription factor", but it also has non-transcriptional functions. These include anti-inflammatory properties that are partially attributed to its transrepression ability. For example, PPARγ can physically bind to NF-κB, preventing nuclear translocation or enhancing transport of NF-κB out of the nucleus (6). Furthermore, PPARγ can be SUMOylated and indirectly inhibit NF-κB by binding to the co-repressor complex on NF-κB DNA-binding sites (42). Recent studies also provide evidence that cytosolic localization of PPARγ1, blocks translocation of PKCα to the membrane in monocytes and macrophages mediating cellular desensitization (39). Thus, PPARγ may bind proteins within the platelet and prevent release of bioactive mediators. It was also recently shown that the nuclear hormone receptors, RXRα and RXRβ, are contained in human platelets and that RXR receptors can bind to the G-protein, Gq, and via a nongenomic mechanism inhibit platelet activation (43). These data support the premise that nuclear receptors may be integral players in protein-protein interactions and cellular signaling separate from their transcriptional roles.

The release of PPARγ in association with PMPs is intriguing. PMPs are an important delivery and cell signaling system in inflammatory and hemostatic processes. PMPs can signal expression of adhesion molecules (28), modulate cell to cell interactions (44), and transfer functional receptors between cell types (45). Our studies show that PPARγ labeled PMP can be internalized by the monocytic cell line, THP-1. In support of our findings, Koppler et al. demonstrated that microparticles released from three different human cell lines were transferred to monocytes and B cells (25). Some released PPARγ is not associated with PMPs, and may be expelled as soluble protein or contained

within platelet-released exosomes, a smaller class of microparticle (40–90 nm) without a pro-coagulant function. The function of platelet-released PPARγ has not yet been elucidated, but it could serve as a biomarker of platelet activation or influence cells that incorporate a PMP. It is well established that PMP stimulation of THP-1 cells induces inflammatory cytokines and cell adhesion molecules (28). Here we provide evidence that internalization of PPARγ-containing PMPs elicits a transcellular attenuation of THP-1 cell activation in the presence of a PPARγ agonist, rosiglitazone. The mechanism of this attenuation is currently under investigation. As previously mentioned, PPARγ activation is known to reduce effects in nucleated cells via non-genomic mechanisms that include protein modification and direct protein/protein binding with key signaling pathways, such as NF-κB and PKCα. It has also been documented that PPARγ agonists can influence cytoskeletal rearrangement in monocytes (46). For example, the phospholipid mediator, platelet-activating factor (PAF), is a potent inflammatory molecule and functions in THP-1 macrophages to promote actin cytoskeletal rearrange-ment. It has been demonstrated that the PPARγ agonist, Pioglitazone, inhibits PAF mediated changes in the macrophage cytoskeleton to down regulate inflammation (47).

Platelet activation and the release of their constituents plays a central role in hemostasis, immunomodulation and inflammation. Our exciting discovery that human platelets release PPARγ and RXR expands the spectrum of proteins contained within these cells. Additionally, we provide the underlying evidence that internalized platelet PPARγ protein appears capable of biologic activity in THP-1 cells. This discovery may represent a novel mechanism of transcellular regulation. Thus, it is important to continue to study the mechanism of PPARγ release and its regulation. Finally, released PPARγ and other proteins could serve as markers that platelets have been activated.

Acknowledgement

References

1. Daynes RA, Jones DC. Emerging roles of PPARs in inflammation and immunity. Nat Rev Immunol 2002; 2: 748–759.
2. Yanase T, Yashiro T, Takitani K, et al. Differential expression of PPAR γl and γ2 isoforms in human adipose tissue. Biochem Biophys Res Commun 1997; 233: 320–324.
3. Padilla J, Leung E, Phipps RP. Human B lymphocytes and B lymphomas express PPAR-γ and are killed by PPAR-γ agonists. Clin Immunol 2002; 103: 22–33.
4. Ricote M, Li AC, Willson TM, et al. The peroxisome proliferator-activated receptor-γ is a negative regulator of macrophage activation. Nature 1998; 391: 79–82.
5. Fajas L, Auboeuf D, Raspe E, et al. The organization, promoter analysis, and expression of the human PPARγ gene. J Biol Chem 1997; 272: 18779–18789.
6. Kelly D, Campbell JI, King TP, et al. Commensal anaerobic gut bacteria attenuate inflammation by regulating nuclear-cytoplasmic shuttling of PPAR-γ and RelA. Nat Immunol 2004; 5: 104–112.
7. Kliewer SA, Umesono K, Noonan DJ, et al. Convergence of 9-cis retinoic acid and peroxisome proliferator signalling pathways through heterodimer formation of their receptors. Nature 1992; 358: 771–774.
8. Lehmann JM, Moore LB, Smith-Oliver TA, et al. An antidiabetic thiazolidinedione is a high affinity ligand for peroxisome proliferator-activated receptor γ (PPAR γ). J Biol Chem 1995; 270: 12953–12956.
9. Forman BM, Tontonoz P, Chen J, et al. 15-Deoxy-Δ$^{12, 14}$-prostaglandin J$_2$ is a ligand for the adipocyte determination factor PPAR γ. Cell 1995; 83: 803–812.
10. Feldon SE, O'Loughlin C W, Ray DM, et al. Activated Human T Lymphocytes Express Cyclooxygenase-2 and Produce Proadipogenic Prostaglandins that Drive Human Orbital Fibroblast Differentiation to Adipocytes. Am J Pathol 2006; 169: 1183–1193.
11. McIntyre TM, Pontsler AV, Silva AR, et al. Identification of an intracellular receptor for lysophosphatidic acid (LPA): LPA is a transcellular PPARg agonist. Proc Natl Acad Sci U S A 2003; 100: 131–136.
12. Investigators TDT. Effect of rosiglitazone on the frequency of diabetes in patients with impaired glucose tolerance or impaired fasting glucose: a randomized controlled trial. Lancet; prepublished online September 15, 2006, doi:10.1016[S0140-6736(06)69420-8

13. Akbiyik F, Ray DM, Gettings KF, et al. Human bone marrow megakaryocytes and platelets express PPARg, and PPARg agonists blunt platelet release of CD40 ligand and thromboxanes. Blood 2004; 104: 1361–1368.
14. Wagner DD, Burger PC. Platelets in inflammation and thrombosis. Arterioscler Thromb Vasc Biol 2003; 23: 2131–2137.
15. Lambert MP, Sachais BS, Kowalska MA. Chemokines and thrombogenicity. Thromb Haemost 2007; 97: 722–729.
16. von Hundelshausen P, Petersen F, Brandt E. Platelet-derived chemokines in vascular biology. Thromb Haemost 2007; 97: 704–713.
17. Henn V, Slupsky JR, Grafe M, et al. CD40 ligand on activated platelets triggers an inflammatory reaction of endothelial cells. Nature 1998; 391: 591–594.
18. Tan KT, Lip GY. The potential role of platelet microparticles in atherosclerosis. Thromb Haemost 2005; 94: 488–492.
19. Blann AD, Tan KT, Tayebjee MH, et al. Soluble CD40L in peripheral artery disease. Relationship with disease severity, platelet markers and the effects of angioplasty. Thromb Haemost 2005; 93: 578–583.
20. Phipps RP. Atherosclerosis: the emerging role of inflammation and the CD40-CD40 ligand system. Proc Natl Acad Sci U S A 2000; 97: 6930–6932.
21. Jackson SP, Schoenwaelder SM. Antiplatelet therapy: in search of the 'magic bullet'. Nat Rev Drug Discov 2003; 2: 775–789.
22. Bode AP, Sandberg H, Dombrose FA, et al. Association of factor V activity with membranous vesicles released from human platelets: requirement for platelet stimulation. Thromb Res 1985; 39: 49–61.
23. Horstman LL, Jy W, Jimenez JJ, et al. New horizons in the analysis of circulating cell-derived microparticles. Keio J Med 2004; 53: 210–230.
24. Weyrich AS, Lindemann S, Zimmerman GA. The evolving role of platelets in inflammation. J Thromb Haemost 2003; 1: 1897–1905.
25. Koppler B, Cohen C, Schlondorff D, et al. Differential mechanisms of microparticle transfer to B cells and monocytes: anti-inflammatory properties of microparticles. Eur J Immunol 2006; 36: 648–660.
26. Sims PJ, Wiedmer T, Esmon CT, et al. Assembly of the platelet prothrombinase complex is linked to ve-

siculation of the platelet plasma membrane. Studies in Scott syndrome: an isolated defect in platelet pro-coagulant activity. J Biol Chem 1989; 264: 17049–17057.
27. Tans G, Rosing J, Thomassen MC, et al. Comparison of anticoagulant and procoagulant activities of stimulated platelets and platelet-derived microparticles. Blood 1991; 77: 2641–2648.
28. Nomura S, Tandon NN, Nakamura T, et al. High-shear-stress-induced activation of platelets and microparticles enhances expression of cell adhesion molecules in THP-1 and endothelial cells. Atherosclerosis 2001; 158: 277–287.
29. Diamant M, Nieuwland R, Pablo RF, et al. Elevated numbers of tissue-factor exposing microparticles correlate with components of the metabolic syndrome in uncomplicated type 2 diabetes mellitus. Circulation 2002; 106: 2442–2447.
30. Janowska-Wiexzorek AKJ, Marquez LA, Ratajczak J, et al. Microvesicles derived from activated platelets: an under-appreciated modulator of the metastatic potential of tumor cells. Blood 2003; 102: 57b #3998.
31. Ogura M, Morishima Y, Ohno R, et al. Establishment of a novel human megakaryoblastic leukemia cell line, MEG-01, with positive Philadelphia chromosome. Blood 1985; 66: 1384–1392.
32. Avanzi GC, Brizzi MF, Giannotti J, et al. M-07e human leukemic factor-dependent cell line provides a rapid and sensitive bioassay for the human cytokines GM-CSF and IL-3. J Cell Physiol 1990; 145: 458–464.
33. Ray DM, Bernstein SH, Phipps RP. Human multiple myeloma cells express peroxisome proliferator-activated receptor γ and undergo apoptosis upon exposure to PPARγ ligands. Clin Immunol 2004; 113: 203–213.
34. Kaiser PC, Korner M, Kappeler A, et al. Retinoid receptors in ovarian cancer: expression and prognosis. Ann Oncol 2005; 16: 1477–1487.
35. Heijnen HF, Schiel AE, Fijnheer R, et al. Activated platelets release two types of membrane vesicles: microvesicles by surface shedding and exosomes derived from exocytosis of multivesicular bodies and alpha-granules. Blood 1999; 94: 3791–3799.
36. Flaumenhaft R, Dilks JR, Rozenvayn N, et al. The actin cytoskeleton differentially regulates platelet

alpha-granule and dense-granule secretion. Blood 2005; 105: 3879–3887.

37. Gnatenko DV, Dunn JJ, McCorkle SR, et al. Transcript profiling of human platelets using microarray and serial analysis of gene expression. Blood 2003; 101: 2285–2293.

38. Leesnitzer LM, Parks DJ, Bledsoe RK, et al. Functional consequences of cysteine modification in the ligand binding sites of peroxisome proliferator activated receptors by GW9662. Biochemistry 2002; 41: 6640–6650.

39. von Knethen A, Soller M, Tzieply N, et al. PPAR-gamma1 attenuates cytosol to membrane translocation of PKCalpha to desensitize monocytes/macrophages. J Cell Biol 2007; 176: 681–694.

40. Fox JE, Austin CD, Boyles JK, et al. Role of the membrane skeleton in preventing the shedding of pro-coagulant-rich microvesicles from the platelet plasma membrane. J Cell Biol 1990; 111: 483–493.

41. Johnson BA, Wilson EM, Li Y, et al. Ligand-induced stabilization of PPARgamma monitored by NMR spectroscopy: implications for nuclear receptor activation. J Mol Biol 2000; 298: 187–194.

42. Pascual G, Fong AL, Ogawa S, et al. A SUMOy-lation-dependent pathway mediates transrepression of inflammatory response genes by PPAR-γ. Nature 2005; 437: 759–763.

43. Moraes LA, Swales KE, Wray JA, et al. Nongenomic signaling of the retinoid X receptor through binding and inhibiting Gq in human platelets. Blood 2007; 109: 3741–3744.

44. Scholz T, Temmler U, Krause S, et al. Transfer of tissue factor from platelets to monocytes: role of pla-telet-derived microvesicles and CD62P. Thromb Haemost 2002; 88: 1033–1038.

45. Janowska-Wieczorek A, Majka M, Kijowski J, et al. Platelet-derived microparticles bind to hematopoietic stem/progenitor cells and enhance their engraftment. Blood 2001; 98: 3143–3149.

46. Singh N, Webb R, Adams R, et al. The PPAR-gamma activator, Rosiglitazone, inhibits actin polymerisation in monocytes: involvement of Akt and intracellular calcium. Biochem Biophys Res Commun 2005; 333: 455–462.

47. Sumita C, Maeda M, Fujio Y, et al. Pioglitazone induces plasma platelet activating factor-acetylhydrolase and inhibits platelet activating factor-mediated cytoskeletal reorganization in macrophage. Biochim Biophys Acta 2004; 1673: 115–121.